The World Health Organization (WHO) emphasizes
and provides global guidance for the equitable
deployment of COVID-19 medical products,
including diagnostics, vaccines and therapeutics
(DVT) and personal protective equipment (PPE).
At the national level, Ministry of Health guidelines
list the recommended DVT and PPE for prevention,
diagnosis and management of COVID-19 in Uganda.
Over the past decade, Uganda has increased financial investments in family planning (FP) and restructured
the commodity supply chain as part of broader FP programming reforms that have enabled the country
make progress on the FP2020 goals. In the light of this progress, HEPS-Uganda undertook an assessment
of the country’s FP financing and supply chain landscape and, in this brief, argues that progress on the
country’s FP2020 targets can be accelerated by establishing a separate contraceptives budget-line;
revitalizing social marketing and the private sector; expediting commodity procurements; advocating for
an FP-inclusive National Health Insurance Scheme (NHIS); and improving demand forecasting.
FP commodities for use in the public sector are included in the Uganda Clinical
Guidelines (UCG) and the Essential Medicines and Health Supplies (EMHS) List
of Uganda. These commodities also must be registered by the National Drug
Authority (NDA). The Ministry of Health’s National RMNCAH Quantification Report
guides GOU and partners on the quantities of commodities required and when to
procure them. Guided by the Supply Plans in the quantification report, GOU and
Health Development Partners (HDPs) make financial commitments and initiate the
procurements of the commodities.
This is the third edition of The People’s Voice; the first was published in 2019 and the second in 2020. This People’s Voice on COP21 focuses on the following critical themes: effective management of COVID-19, It also focuses on the promotion of quality, evidence-based, and human rights prevention interventions; expanding biomedical and structural prevention interventions for women and girls including GBV, economic empowerment, and human rights; support for people with disabilities; closing gaps in diagnosis and treatment of children with HIV.
Uganda has an estimated 1,392,742 people living with HIV (PLHIV), consisting of 1,296,000 adults aged 15-64 years (6.2% prevalence) and 96742 children aged 0-14 years (0.5% prevalence). Prevalence is higher among women (7.6%) than among men(4.7%) and among young people (15-24 years), prevalence is four times higher among adolescent girls and young women (3.3%) than among adolescent boys and young men(0.8%). New infections are estimated at 80,500 people per year; 73,000 adults and 7,500 children. Approximately 83% of HIV-positive Ugandans currently access HIV treatment. Despite important progress made by the country towards the national target of reaching epidemic control, Uganda continues to face major challenges that are weakening the impact of the national response.